SG10201704611WA - Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use - Google Patents
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and useInfo
- Publication number
- SG10201704611WA SG10201704611WA SG10201704611WA SG10201704611WA SG10201704611WA SG 10201704611W A SG10201704611W A SG 10201704611WA SG 10201704611W A SG10201704611W A SG 10201704611WA SG 10201704611W A SG10201704611W A SG 10201704611WA SG 10201704611W A SG10201704611W A SG 10201704611WA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- preparation
- methods
- cyclic purine
- purine dinucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261737006P | 2012-12-13 | 2012-12-13 | |
US201361790514P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201704611WA true SG10201704611WA (en) | 2017-07-28 |
Family
ID=50935019
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201704611WA SG10201704611WA (en) | 2012-12-13 | 2013-12-13 | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
SG11201502796RA SG11201502796RA (en) | 2012-12-13 | 2013-12-13 | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201502796RA SG11201502796RA (en) | 2012-12-13 | 2013-12-13 | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
Country Status (19)
Country | Link |
---|---|
US (2) | US9695212B2 (fr) |
EP (2) | EP2931738B1 (fr) |
JP (2) | JP6333843B2 (fr) |
KR (1) | KR20150095668A (fr) |
CN (2) | CN105008381B (fr) |
AU (2) | AU2013358892B2 (fr) |
BR (1) | BR112015013440B1 (fr) |
CA (1) | CA2886456A1 (fr) |
DK (1) | DK2931738T3 (fr) |
EA (1) | EA201590396A1 (fr) |
ES (1) | ES2718910T3 (fr) |
HK (1) | HK1212707A1 (fr) |
HU (1) | HUE043262T2 (fr) |
MX (1) | MX361680B (fr) |
PL (1) | PL2931738T3 (fr) |
PT (1) | PT2931738T (fr) |
SG (2) | SG10201704611WA (fr) |
SI (1) | SI2931738T1 (fr) |
WO (1) | WO2014093936A1 (fr) |
Families Citing this family (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012048165A2 (fr) | 2010-10-06 | 2012-04-12 | President And Fellows Of Harvard College | Hydrogels injectable, gélifiants pour des thérapies cellulaires à base de matériaux |
WO2013185052A1 (fr) * | 2012-06-08 | 2013-12-12 | Aduro Biotech | Compositions et procédés pour immunothérapie anticancéreuse |
WO2014093936A1 (fr) | 2012-12-13 | 2014-06-19 | Aduro Biotech, Inc. | Compositions comprenant des dinucléotides cycliques de purine présentant des stéréochimies définies et procédés pour leur préparation et leur utilisation |
CA2895175C (fr) | 2012-12-19 | 2021-06-01 | Board Of Regents, The University Of Texas System | Ciblage pharmaceutique d'une voie de signalisation de dinucleotide cyclique chez un mammifere |
BR112015027327B1 (pt) | 2013-04-29 | 2022-08-02 | Rutgers, The State University Of New Jersey | Composto, modulador de cgas, composição farmacêutica compreendendo o referido composto ou modulador |
CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
JP6453855B2 (ja) | 2013-05-18 | 2019-01-16 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 |
JP6400082B2 (ja) * | 2013-05-18 | 2018-10-03 | アデュロ バイオテック,インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
WO2015017652A1 (fr) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Cristaux sting et modulateurs associés |
US20160287623A1 (en) * | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
CN103908468B (zh) * | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
JP6462006B2 (ja) | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingのモジュレーターとしての環式ジヌクレオチド |
WO2016079899A1 (fr) * | 2014-11-20 | 2016-05-26 | 国立研究開発法人医薬基盤・健康・栄養研究所 | NOUVEL ADJUVANT INDUCTEUR DE Th1 COMPRENANT UNE ASSOCIATION DE DIFFÉRENTS ADJUVANTS DE TYPE ACIDE NUCLÉIQUE, ET SON UTILISATION |
EP3233882B1 (fr) | 2014-12-16 | 2019-10-30 | Kayla Therapeutics | Dinucléotides cycliques fluorés pour l'induction de la cytokine |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
CA3013713A1 (fr) | 2015-02-11 | 2016-08-18 | The Johns Hopkins University | Bacteries surexprimant la molecule c-di-amp et methodes therapeutiques associees |
KR20170129802A (ko) * | 2015-03-10 | 2017-11-27 | 아두로 바이오테크, 인코포레이티드 | "인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법 |
US11571462B2 (en) | 2015-06-03 | 2023-02-07 | The Medical College Of Wisconsin, Inc. | Engineered CCL20 locked dimer polypeptide |
AU2016271292B2 (en) | 2015-06-03 | 2022-04-14 | The Medical College Of Wisconsin, Inc. | An engineered CCL20 locked dimer polypeptide |
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
GEP20207182B (en) | 2015-08-13 | 2020-11-25 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
MA48579A (fr) | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
CN105367617A (zh) * | 2015-09-25 | 2016-03-02 | 武汉品生科技有限公司 | 一种基于环二腺核苷酸的衍生物、tat多肽及其在一型干扰素小分子中抑制剂的应用 |
AU2016343993A1 (en) | 2015-10-28 | 2018-05-10 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
CN106539813B (zh) * | 2015-11-30 | 2019-12-03 | 杭州星鳌生物科技有限公司 | 干扰素刺激基因(sting)激活剂在抗炎症中的应用 |
MA52157A (fr) | 2015-12-03 | 2021-02-17 | Glaxosmithkline Ip Dev Ltd | Dinucléotides cycliques de purine utilisés comme modulateurs de sting |
CN106540260A (zh) * | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白(sting)激动剂在抗阿尔兹海默症中的应用 |
CN106554416B (zh) * | 2015-12-09 | 2019-03-15 | 聊城市奥润生物医药科技有限公司 | 一种抗pd-l1人源化单克隆抗体联合干扰素基因刺激蛋白(sting)激动剂在抗肿瘤中的应用 |
CN106539814A (zh) * | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白(sting)激动剂在抗类风湿性关节炎等疾病中的应用 |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
WO2017106740A1 (fr) * | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Procédés servant à identifier des inhibiteurs de la production d'interféron dépendant du stimulateur du gène d'interféron |
CN109451740B (zh) | 2016-01-11 | 2022-09-02 | 先天肿瘤免疫公司 | 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸 |
JP2019511483A (ja) * | 2016-03-02 | 2019-04-25 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 免疫療法のためのsting活性化ナノワクチン |
IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
CN106539757A (zh) * | 2016-03-20 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用 |
CR20200045A (es) | 2016-04-07 | 2020-03-11 | Glaxosmithkline Ip Dev Ltd | AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472) |
EP3440072B1 (fr) | 2016-04-07 | 2020-01-29 | GlaxoSmithKline Intellectual Property Development Ltd | Amides hétérocycliques utiles en tant que modulateurs de protéine |
WO2017186711A1 (fr) | 2016-04-25 | 2017-11-02 | Invivogen | Nouveaux complexes de composés immunostimulateurs, et leurs utilisations |
US10696985B1 (en) | 2016-06-06 | 2020-06-30 | Vanderbilt University | Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery |
WO2018009466A1 (fr) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
EP3481402A4 (fr) * | 2016-07-06 | 2020-01-22 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
US10300145B2 (en) | 2016-07-15 | 2019-05-28 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
DE102016113714A1 (de) | 2016-07-26 | 2018-02-01 | Rosa Karl | Transfektionsverfahren mit nicht-viralen Genliefersystemen |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
EP3506884B1 (fr) | 2016-08-30 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Compositions pour la délivrance médicaments et leurs utilisations |
WO2018053508A1 (fr) * | 2016-09-19 | 2018-03-22 | The University Of North Carolina At Chapel Hill | Méthodes et compositions pour induire une réponse immunitaire |
US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
RS62410B1 (sr) | 2016-10-04 | 2021-10-29 | Merck Sharp & Dohme | Benzo[b]tiofenska jedinjenja kao agonisti sting |
US10266558B2 (en) * | 2016-10-07 | 2019-04-23 | Alexandre Vasilievich Ivachtchenko | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |
US11001605B2 (en) | 2016-10-07 | 2021-05-11 | Biolog Life Science Institute Gmbh & Co. Kg | Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways |
JOP20170192A1 (ar) * | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
WO2018119117A1 (fr) * | 2016-12-22 | 2018-06-28 | The Regents Of The University Of California | Procédés de production de dinucléotides cycliques |
JP2018131427A (ja) * | 2017-02-17 | 2018-08-23 | 国立研究開発法人理化学研究所 | 免疫細胞の制御技術 |
US20200055883A1 (en) * | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
CA3053568A1 (fr) | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Dinucleotides cycliques utilises en tant qu'agonistes du stimulateur de la signalisation dependante du gene de l'interferon |
CN106928298B (zh) * | 2017-03-13 | 2021-10-22 | 杭州星鳌生物科技有限公司 | 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用 |
JOP20190218A1 (ar) | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
US10851164B2 (en) | 2017-04-13 | 2020-12-01 | Aduro Biotech Holdings, Europe B.V. | Anti-SIRPα antibodies |
MX2019012295A (es) | 2017-04-14 | 2020-02-07 | Tollnine Inc | Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso. |
AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
US11969499B2 (en) | 2017-06-16 | 2024-04-30 | William Marsh Rice University | Hydrogel delivery of sting immunotherapy for treatment cancer |
AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
WO2019043634A2 (fr) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | Di-nucléotides cycliques en tant que stimulateurs de modulateurs de gènes d'interféron |
JP7270608B2 (ja) | 2017-08-31 | 2023-05-10 | エフ-スター・セラピューティクス・インコーポレイテッド | 化合物、組成物、及び疾患の治療方法 |
US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
MX2020002901A (es) | 2017-09-19 | 2020-07-22 | Massachusetts Inst Technology | Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas. |
AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
WO2019069270A1 (fr) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulateurs de stimulateur des gènes (sting) de l'interféron |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
US11542293B2 (en) | 2017-11-10 | 2023-01-03 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
WO2019099578A1 (fr) | 2017-11-14 | 2019-05-23 | Chidren's Medical Center Corporation | Utilisation d'imidazopyrimidine pour moduler une réponse immunitaire humaine |
WO2019099564A1 (fr) | 2017-11-14 | 2019-05-23 | Children's Medical Center Corporation | Nouveaux composés d'imidazopyrimidine et leurs utilisations |
KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
CA3084582A1 (fr) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucleotides 2'3' cycliques ayant une liaison phosphonate activant la proteine adaptatrice de sting |
WO2019123340A1 (fr) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting |
EP3727401A4 (fr) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | Composés dinucléotidiques cycliques utilisés comme agonistes sting |
WO2019161171A1 (fr) * | 2018-02-16 | 2019-08-22 | Sperovie Biosciences, Inc. | Formulations de nanoparticules d'agonistes de sting |
MX2020009796A (es) | 2018-03-23 | 2021-01-15 | Codiak Biosciences Inc | Vesiculas extracelulares que comprenden agonista de estimulador de genes de interferon (sting). |
CN111989338A (zh) | 2018-03-27 | 2020-11-24 | 勃林格殷格翰国际有限公司 | 修饰的环二核苷酸化合物 |
EP3774834A1 (fr) | 2018-03-27 | 2021-02-17 | Boehringer Ingelheim International GmbH | Composés dinucléotidiques cycliques contenant 2-aza-hypoxanthine ou 6h-pytazolo[1,5-d][1,2,4]triazine-7-one en tant qu'agonistes de sting |
CA3095646A1 (fr) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes et composes associes utilises en tant qu'agonistes de sting |
WO2019195063A1 (fr) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
JP7296398B2 (ja) | 2018-04-06 | 2023-06-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチド |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
WO2019227007A1 (fr) | 2018-05-25 | 2019-11-28 | Incyte Corporation | Composés hétérocycliques tricycliques en tant qu'activateurs de sting |
BR112020024605A2 (pt) | 2018-06-01 | 2021-04-06 | Eisai R&D Management Co., Ltd. | Métodos para o tratamento de câncer de bexiga |
US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
US11564993B2 (en) | 2018-08-03 | 2023-01-31 | The University Of Tokyo | Intranasal vaccine that induces cellular immunity |
CN112041325B (zh) | 2018-08-16 | 2023-10-24 | 卫材R&D管理有限公司 | 化合物的盐及其晶体 |
AU2019337051B2 (en) | 2018-09-06 | 2023-11-23 | Daiichi Sankyo Company, Limited | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
JP2021535930A (ja) * | 2018-09-17 | 2021-12-23 | キュラティス インコーポレイティッド | Stingアゴニストを含む抗原性補強剤及びワクチン組成物 |
CA3113425A1 (fr) | 2018-09-21 | 2020-03-26 | Shanghai De Novo Pharmatech Co., Ltd. | Analogue dinucleotidique cyclique, composition pharmaceutique associee et utilisation |
US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
WO2020092633A1 (fr) | 2018-10-30 | 2020-05-07 | Vanderbilt University | Copolymères greffés, procédés de formation de copolymères greffés et procédés d'utilisation correspondants |
JP2022509929A (ja) | 2018-10-31 | 2022-01-25 | ノバルティス アーゲー | Stingアゴニストを含むdc-sign抗体コンジュゲート |
US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
JP7224688B2 (ja) * | 2019-01-10 | 2023-02-20 | 南▲開▼大学 | 環状ジヌクレオチドプロドラッグ分子、その製造方法及び使用 |
EP3935065A1 (fr) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
EP3934757B1 (fr) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
WO2020191369A1 (fr) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Procédé de préparation de vésicules extracellulaires |
CN113747925A (zh) | 2019-03-21 | 2021-12-03 | 科迪亚克生物科学公司 | 胞外囊泡缀合物及其用途 |
US20220168415A1 (en) | 2019-03-21 | 2022-06-02 | Codiak Biosciences, Inc. | Extracellular vesicles for vaccine delivery |
US20220177465A1 (en) | 2019-04-04 | 2022-06-09 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes |
TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
EP3962493A2 (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Métodes de modulation de l'activité immunitaire |
US11787833B2 (en) | 2019-05-09 | 2023-10-17 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
JP2022532192A (ja) | 2019-05-10 | 2022-07-13 | 武田薬品工業株式会社 | 抗体薬物複合体 |
US20230181758A1 (en) | 2019-07-03 | 2023-06-15 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
WO2021003445A1 (fr) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Vésicules extracellulaires ciblant des lymphocytes t et leurs utilisations |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
JP2022543086A (ja) | 2019-08-02 | 2022-10-07 | メルサナ セラピューティクス インコーポレイテッド | がんの処置用のSTING(インターフェロン遺伝子刺激因子)アゴニストとしてのビス-[N-((5-カルバモイル)-1H-ベンゾ[d]イミダゾール-2-イル)-ピラゾール-5-カルボキサミド]誘導体および関連化合物 |
MX2022001732A (es) | 2019-08-12 | 2022-05-06 | Purinomia Biotech Inc | Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39. |
WO2021041532A1 (fr) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Utilisation d'héparine pour favoriser la signalisation de l'interféron de type 1 |
EP3785719A1 (fr) * | 2019-08-28 | 2021-03-03 | Helmholtz-Zentrum für Infektionsforschung GmbH | Nouvelle utilisation de dinucléotides cycliques |
WO2021062058A1 (fr) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Agoniste de sting comprenant des exosomes pour le traitement de troubles neuro-immunologiques |
EP4034276A1 (fr) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Procédés de production de vésicules extracellulaires |
AU2020355240A1 (en) | 2019-09-25 | 2022-04-21 | Lonza Sales Ag | Extracellular vesicle compositions |
KR20220094221A (ko) | 2019-09-25 | 2022-07-05 | 코디악 바이오사이언시즈, 인크. | 종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀 |
WO2021074695A1 (fr) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | FRACTIONS DE MÉDICAMENTS BISPÉCIFIQUES DE L'INHIBITEUR DE PD-L1 ET DE L'INHIBITEUR DE TGFβ |
EP4069683A1 (fr) | 2019-12-06 | 2022-10-12 | Mersana Therapeutics, Inc. | Composés dimères utilisés en tant qu'agonistes de sting |
US11744874B2 (en) | 2019-12-20 | 2023-09-05 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof |
WO2021168274A1 (fr) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
MX2022010515A (es) | 2020-02-28 | 2022-11-14 | Tallac Therapeutics Inc | Conjugacion mediada por transglutaminasa. |
IL296124A (en) | 2020-03-06 | 2022-11-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a drug including a novel cyclic dinucleotide derivative |
WO2021184017A1 (fr) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Vésicules extracellulaires pour le traitement de troubles neurologiques |
JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ, インコーポレイテッド | 治療のための細胞外小胞 |
EP4134098A4 (fr) | 2020-04-10 | 2024-05-15 | Ono Pharmaceutical Co | Méthode de cancérothérapie |
WO2021216572A1 (fr) | 2020-04-20 | 2021-10-28 | Massachusetts Institute Of Technology | Compositions lipidiques pour l'administration de composés agonistes de sting et leurs utilisations |
WO2021221783A1 (fr) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Procédés d'identification de ligands de ciblage de récepteur antigénique chimérique et leurs utilisations |
WO2021221782A1 (fr) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Ligands chimériques ciblant des récepteurs antigéniques et leurs utilisations |
IL298019A (en) | 2020-05-13 | 2023-01-01 | Massachusetts Inst Technology | Compositions of polymeric microdevices and their use in cancer immunotherapy |
WO2021237100A1 (fr) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Procédés d'administration ciblée de vésicules extracellulaires dans le poumon |
AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
JPWO2022050300A1 (fr) | 2020-09-02 | 2022-03-10 | ||
WO2022066928A2 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Procédé de préparation de vésicules extracellulaires |
WO2022066883A1 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Vésicules extracellulaires comprenant des antigènes kras et leurs utilisations |
US20240082389A1 (en) | 2020-09-23 | 2024-03-14 | Lonza Sales Ag | Methods of producing extracellular vesicles |
WO2022066934A2 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Procédé de préparation de vésicules extracellulaires |
EP4228681A1 (fr) | 2020-10-14 | 2023-08-23 | Boehringer Ingelheim International GmbH | Association d'un agoniste de sting et d'un complexe comprenant un peptide de pénétration cellulaire, une cargaison et un agoniste peptidique de tlr |
US20240059729A1 (en) * | 2020-10-20 | 2024-02-22 | Tyligand Bioscience (Shanghai) Limited | Multifunctional cyclic dinucleotide and use thereof |
MX2023005381A (es) | 2020-11-09 | 2023-05-23 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco. |
CN116981479A (zh) | 2020-12-17 | 2023-10-31 | 塔夫茨大学信托人 | Fap激活的放射治疗诊断法以及与之相关的用途 |
EP4032545A1 (fr) * | 2021-01-26 | 2022-07-27 | Medizinische Hochschule Hannover | Composition immunogène et vaccin contenant des antigènes de surface du chlamydia spp. et son utilisation |
EP4326321A1 (fr) | 2021-04-20 | 2024-02-28 | Institut Curie | Compositions et procédés destinés à être utilisés en immunothérapie |
JP2024514707A (ja) | 2021-04-20 | 2024-04-02 | アンスティテュ・クリー | 免疫療法における使用のための組成物及び方法 |
WO2022234003A1 (fr) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Polypeptides se liant à cd33 avec protéine stefin a |
WO2023056468A1 (fr) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Vésicule extracellulaire comprenant un agoniste de sting marqué au cholestérol |
TW202334196A (zh) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1結合多肽 |
US20230414763A1 (en) | 2022-03-04 | 2023-12-28 | Massachusetts Institute Of Technology | Transmucosal amphiphile-protein conjugate vaccine |
WO2023218243A1 (fr) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Protéines de fusion de liaison lag-3/pd-l1 |
WO2024036275A1 (fr) * | 2022-08-10 | 2024-02-15 | Aldevron Llc | Procédés de production de dinucléotides cycliques |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9110808D0 (en) | 1991-05-17 | 1991-07-10 | Retroscreen Ltd | Aids vaccine and method for its production |
GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
IT1262895B (it) | 1992-03-02 | 1996-07-22 | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
US5635160A (en) | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
US6033674A (en) | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
US6464973B1 (en) | 1998-02-02 | 2002-10-15 | Johns Hopkins University, School Of Medicine | Universal GM-CSF expressing bystander human K562 cell line |
RU2238279C2 (ru) | 1999-02-15 | 2004-10-20 | Ниппон Синяку Ко., Лтд. | Полинуклеотид с укороченной цепью и способ его получения |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
EP1320602A2 (fr) | 2000-09-21 | 2003-06-25 | The Regents Of The University Of California | Antigene du cancer spas-1 |
NZ525320A (en) * | 2000-10-18 | 2004-10-29 | Glaxosmithkline Biolog S | Combinations of immunostimulatory oligonucleotides (CpG), saponin and optionally lipopolysaccharides as potent vaccine adjuvants |
US7279883B2 (en) | 2001-01-23 | 2007-10-09 | Lydia L. Sohn | Particle analyzer and methods for use thereof |
TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
EP1651242A2 (fr) | 2003-07-28 | 2006-05-03 | David K. R. Karaolis | Procede permettant d'attenuer la virulence d'agents pathogenes microbiens et d'inhiber la formation d'un biofilm microbien |
KR20060130038A (ko) | 2003-10-15 | 2006-12-18 | 메디뮨 인코포레이티드 | 리스테리아에 의거한 EphA2 백신 |
KR20060123170A (ko) * | 2003-10-24 | 2006-12-01 | 알자 코포레이션 | 지질 입자의 제조방법 |
US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
US7709458B2 (en) * | 2004-03-15 | 2010-05-04 | David K. R. Karaolis | Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
US20060286549A1 (en) | 2005-05-06 | 2006-12-21 | The Regents Of The University Of California | Microfluidic system for identifying or sizing individual particles passing through a channel |
US20070059683A1 (en) | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
EP1782826A1 (fr) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS, c-diGMP et leurs conjugués utilisés comme adjuvants et leur emploi dans des compositions pharmaceutiques |
EP3000480A1 (fr) | 2005-12-01 | 2016-03-30 | ProNAi Therapeutics, Inc. | Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies |
CA2659301A1 (fr) * | 2006-07-28 | 2008-02-07 | Applera Corporation | Analogues de coiffes de nucleotide d'arnm |
EP2059802A4 (fr) | 2006-09-05 | 2010-09-08 | Bipar Sciences Inc | Procedes de conception d'inhibiteurs de parp et leurs utilisations |
TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
EP2324044A4 (fr) | 2008-08-04 | 2012-04-25 | Univ Miami | Sting (stimulateur de gènes d interféron), un régulateur de réponses immunitaires innées |
US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
PL2376107T3 (pl) * | 2008-12-09 | 2014-09-30 | Coley Pharm Group Inc | Oligonukleotydy immunostymulujące |
EP2405758B1 (fr) | 2009-03-09 | 2016-04-27 | Molecular Express, Inc. | Procédés et compositions pour formulation liposomale d'antigènes et leurs utilisations |
US8414630B2 (en) | 2009-03-10 | 2013-04-09 | Marc Evan Richelsoph | Active bone screw |
ES2606563T3 (es) | 2009-06-05 | 2017-03-24 | Infectious Disease Research Institute | Adyuvantes lipídicos de glucopiranosilo sintéticos y composiciones de vacuna que contienen los mismos |
US20120178710A1 (en) | 2009-07-01 | 2012-07-12 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
US8771933B2 (en) | 2009-10-06 | 2014-07-08 | Massachusetts Institute Of Technology | Continuous-flow deformability-based cell separation |
WO2011073326A2 (fr) * | 2009-12-18 | 2011-06-23 | Novartis Ag | Compositions organiques de traitement des pathologies liées à hsf1 |
EP2361911A1 (fr) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Dérivés de pyrazolo pipéridine en tant qu'inhibiteurs de la NADPH oxydase |
US20120064505A1 (en) | 2010-03-22 | 2012-03-15 | Massachusetts Institute Of Technology | Measurement of material properties and related methods and compositions |
CN102199183B (zh) | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
WO2011136828A1 (fr) | 2010-04-27 | 2011-11-03 | The Johns Hopkins University | Compositions immunogènes et méthodes de traitement d'une néoplasie |
US8450293B2 (en) | 2010-08-10 | 2013-05-28 | Rutgers, The State University Of New Jersey | Synthesis and characterization of C8 analogs of c-di-GMP |
CN103415620B (zh) | 2010-11-17 | 2016-10-12 | 艾杜罗生物科技公司 | 诱导针对EGFRvIII的免疫应答的方法和组合物 |
US9061048B2 (en) | 2010-12-15 | 2015-06-23 | The Regents Of The University Of California | Cyclic di-AMP induction of type I interferon |
CA2819041A1 (fr) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Analogues de nucleotides cycliques |
CA2833026A1 (fr) | 2011-04-15 | 2012-10-18 | The University Of British Columbia | Procede et appareil de separation de particules |
WO2013086331A1 (fr) | 2011-12-07 | 2013-06-13 | President And Fellows Of Harvard College | Cyclase di-nucléotide à haute efficacité |
CA2907616A1 (fr) | 2012-04-30 | 2013-11-07 | Glen N. Barber | Modulation de reponses immunitaires |
WO2013185052A1 (fr) | 2012-06-08 | 2013-12-12 | Aduro Biotech | Compositions et procédés pour immunothérapie anticancéreuse |
CN112587658A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
US9090646B2 (en) | 2012-12-05 | 2015-07-28 | Rutgers, The State University Of New Jersey | Biotinylated compounds |
WO2014093936A1 (fr) | 2012-12-13 | 2014-06-19 | Aduro Biotech, Inc. | Compositions comprenant des dinucléotides cycliques de purine présentant des stéréochimies définies et procédés pour leur préparation et leur utilisation |
CA2895175C (fr) | 2012-12-19 | 2021-06-01 | Board Of Regents, The University Of Texas System | Ciblage pharmaceutique d'une voie de signalisation de dinucleotide cyclique chez un mammifere |
BR112015027327B1 (pt) | 2013-04-29 | 2022-08-02 | Rutgers, The State University Of New Jersey | Composto, modulador de cgas, composição farmacêutica compreendendo o referido composto ou modulador |
CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
JP6453855B2 (ja) * | 2013-05-18 | 2019-01-16 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 |
JP6400082B2 (ja) | 2013-05-18 | 2018-10-03 | アデュロ バイオテック,インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
WO2015017652A1 (fr) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Cristaux sting et modulateurs associés |
AU2014340269B2 (en) | 2013-10-21 | 2018-06-21 | Drexel University | Use of STING agonists to treat chronic hepatitis B virus infection |
US20160287623A1 (en) | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
WO2015074145A1 (fr) | 2013-11-22 | 2015-05-28 | Brock University | Utilisation de dinucléotides cycliques fluorés comme adjuvants de vaccin oral |
WO2015085565A1 (fr) | 2013-12-13 | 2015-06-18 | Qualcomm Incorporated | Procédés et appareil de sélection de cellule dans un système de communication sans fil |
US10421971B2 (en) | 2014-01-15 | 2019-09-24 | The University Of Chicago | Anti-tumor therapy |
JP6462006B2 (ja) | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingのモジュレーターとしての環式ジヌクレオチド |
EP3233882B1 (fr) | 2014-12-16 | 2019-10-30 | Kayla Therapeutics | Dinucléotides cycliques fluorés pour l'induction de la cytokine |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
KR20170129802A (ko) * | 2015-03-10 | 2017-11-27 | 아두로 바이오테크, 인코포레이티드 | "인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법 |
GEP20207182B (en) | 2015-08-13 | 2020-11-25 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
MA52157A (fr) | 2015-12-03 | 2021-02-17 | Glaxosmithkline Ip Dev Ltd | Dinucléotides cycliques de purine utilisés comme modulateurs de sting |
-
2013
- 2013-12-13 WO PCT/US2013/075189 patent/WO2014093936A1/fr active Application Filing
- 2013-12-13 CN CN201380065216.XA patent/CN105008381B/zh active Active
- 2013-12-13 SG SG10201704611WA patent/SG10201704611WA/en unknown
- 2013-12-13 MX MX2015007447A patent/MX361680B/es active IP Right Grant
- 2013-12-13 CA CA2886456A patent/CA2886456A1/fr not_active Abandoned
- 2013-12-13 CN CN201810801443.9A patent/CN108542913A/zh active Pending
- 2013-12-13 DK DK13863379.7T patent/DK2931738T3/en active
- 2013-12-13 EA EA201590396A patent/EA201590396A1/ru unknown
- 2013-12-13 HU HUE13863379A patent/HUE043262T2/hu unknown
- 2013-12-13 SI SI201331392T patent/SI2931738T1/sl unknown
- 2013-12-13 KR KR1020157015489A patent/KR20150095668A/ko active IP Right Grant
- 2013-12-13 EP EP13863379.7A patent/EP2931738B1/fr active Active
- 2013-12-13 EP EP19151113.8A patent/EP3527579A1/fr not_active Withdrawn
- 2013-12-13 PT PT13863379T patent/PT2931738T/pt unknown
- 2013-12-13 AU AU2013358892A patent/AU2013358892B2/en not_active Ceased
- 2013-12-13 BR BR112015013440-8A patent/BR112015013440B1/pt not_active IP Right Cessation
- 2013-12-13 US US14/106,687 patent/US9695212B2/en active Active
- 2013-12-13 SG SG11201502796RA patent/SG11201502796RA/en unknown
- 2013-12-13 JP JP2015548023A patent/JP6333843B2/ja not_active Expired - Fee Related
- 2013-12-13 PL PL13863379T patent/PL2931738T3/pl unknown
- 2013-12-13 ES ES13863379T patent/ES2718910T3/es active Active
-
2016
- 2016-01-21 HK HK16100666.5A patent/HK1212707A1/zh not_active IP Right Cessation
-
2017
- 2017-06-22 US US15/630,741 patent/US10414789B2/en active Active
-
2018
- 2018-04-25 JP JP2018084405A patent/JP6704012B2/ja active Active
- 2018-05-25 AU AU2018203682A patent/AU2018203682B2/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212707A1 (zh) | 包含具有確定立體化學的環嘌呤二核苷酸的組合物及其製備和使用方法 | |
HK1247566A1 (zh) | 使皮膚回春的組合物和方法 | |
EP2836212A4 (fr) | Nouvelles compositions et nouveaux procédés | |
ZA201408594B (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
IL233681A0 (en) | Pharmacy preparations and methods | |
EP2680837A4 (fr) | Compositions et procédés comprenant du c16:1n7-palmitoléate | |
HK1206970A1 (en) | Antigenic compositions and methods | |
EP2855769A4 (fr) | Papier-mouchoir comprenant des macroalgues | |
ZA201408674B (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
GB201315350D0 (en) | Methods and compositions | |
EP2931324A4 (fr) | Compositions et procédés de régénération tissulaire | |
GB201315347D0 (en) | Methods and compositions | |
EP2807256A4 (fr) | Myonectine (ctrp15), composition la comprenant et procédés d'utilisation | |
ZA201500450B (en) | Novel rebamipide prodrugs, preparation method and use thereof | |
EP2852662A4 (fr) | Compositions de virus herpétique et procédés associés | |
ZA201308892B (en) | Compositions and methods | |
EP2766357A4 (fr) | Compositions méso-biliverdines et procédés associés | |
HK1214267A1 (zh) | 組合物和改善葡萄糖攝取的方法 | |
EP2924021A4 (fr) | Composé anti-vih et procédé de préparation et utilisation correspondants | |
EP2879652A4 (fr) | Compositions et méthodes d'embellissement des cheveux | |
EP2834635A4 (fr) | Compositions d'agents de charge d'héparine et procédés associés | |
GB201208315D0 (en) | Pharmaceutical methods and compositions | |
GB201116340D0 (en) | Compositions and methods |